Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective study published in the Journal of the American ...

Two new studies demonstrate the impact of respiratory syncytial virus (RSV) in different populations, with one showing that ...

An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV) prophylaxis, according to a study published online July ...